Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2161 to 2175 of 7682 results

  1. Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease TS ID 11991

    Awaiting development [GID-TA11518] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]

    In development [GID-TA11425] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. DCVax-L for treating glioblastoma [ID836]

    In development [GID-TA10143] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular or marginal zone lymphoma after 1 or more anti-CD20 treatments ID6413

    Awaiting development [GID-TA11488] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage ID6412 small-cell lung cancer TS ID 11975

    Awaiting development [GID-TA11497] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor TSID 11812

      Status ...

    Health technology evaluations
    Topic selection

  7. Transcatheter Tricuspid Valve Replacement

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  8. Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]

    In development [GID-TA10428] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Memokath 051 Ureter stent for ureteric obstruction (MTG75)

    Evidence-based recommendations on Memokath 051 Ureter stent for ureteric obstruction.

    Medical technologies guidance
    Published
    7 December 2022
    View recommendations

    Sections for MTG75

  10. AposHealth for knee osteoarthritis (MTG76)

    Evidence-based recommendations on AposHealth for knee osteoarthritis.

    Medical technologies guidance
    Published
    11 April 2023
    View recommendations

    Sections for MTG76

  11. Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer (MTG72)

    Evidence-based recommendations on Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer.

    Medical technologies guidance
    Published
    5 October 2022
    View recommendations

    Sections for MTG72

  12. Durvalumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6168]

    Awaiting development [GID-TA11115] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]

    Awaiting development [GID-TA11365] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]

    In development [GID-TA11215] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. The Sherlock 3CG Tip Confirmation System for placement of peripherally inserted central catheters (MTG24)

    Evidence-based recommendations on The Sherlock 3CG Tip Confirmation System for placement of peripherally inserted central catheters.

    Medical technologies guidance
    Last updated
    30 May 2019
    View recommendations

    Sections for MTG24